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MUC1 mucin is aberrantly glycosylated and overexpressed in a number of epithelial malignancies and is therefore a promising
tumour-associated antigen for target-directed immunotherapy of a panel of malignant diseases. In MUC1-positive tumours, MHC
class I expession is frequently downregulated and MUC1-specific cytotoxic T cells (CTLs) are either not available or in a state of
anergy allowing tumour growth without limitation by CTL control. To activate lymphocytes and natural killer (NK) cells, we here
generated an anti-MUC1-scFv-IL2 fusion protein (C595scFv-Fc-IL2) that contains the C595 single-chain antibody for MUC1 binding,
the human IgG1 CH2CH3 domain for protein dimerisation, and interleukin-2 (IL2) for activation of immunological effector cells. The
fusion protein binds to MUC1-derived peptides and to MUC1-positive tumour cells with the same specificity as does the C595
monoclonal antibody. Bound to MUC1, the C595scFv-Fc-IL2 fusion protein stimulates proliferation of human activated lymphocytes
in vitro. Upon binding to MUC1-positive MCF7 breast carcinoma cells, moreover, the fusion protein activates resting NK cells to
tumour cell lysis. These properties make the C595scFv-Fc-IL2 fusion protein a suitable candidate for the immunotherapy of MUC1-
positive tumours.
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MUC1 is a high molecular weight, type 1 transmembrane mucin
with 450% carbohydrates O-linked to the protein core through
serine and threonine. The unique extracellular mucin domain
consists of variable numbers of tandemly repeated peptides (VNTR
domain), each of them made up of 20 amino-acid sequences. The
VNTR domain varies in length from 20 to over 100 repeats
depending on the different alleles, exhibits a sequence polymorph-
ism, and is characterised by differentiation-dependent profiles of
complex glycans that control antigenicity and immunogenicity of
the mucin (Hanisch and Mu ¨ller, 2000). MUC1 is expressed on the
luminal surfaces of glandular epithelial cells of respiratory,
gastrointestinal and genitourinary tracts as well as of pancreatic
and mammary ducts. Adenocarcinomas from these organs
frequently overexpress and aberrantly glycosylate MUC1 leading
to the suggestion that loss of MUC1 topological restriction and
increased cellular expression in cancer cells may contribute to the
malignant phenotype (Hilkens et al, 1992). As MUC1 is secreted by
tumour cells, determination of the levels of MUC1 antigen in the
blood has been exploited as a measure of tumour burden and
changing levels as a reflection of the response to therapy (Berruti
et al, 1994; Martoni et al, 1995).
Patients with MUC1-positive tumours develop both humoral
and cellular immune responses against determinants on the MUC1
antigen from malignant cells as measured by in vitro parameters
(Jerome et al, 1991; Rughetti et al, 1993; Kotera et al, 1994;
Domenech et al, 1995; Hamanaka et al, 2003). Breast and
pancreatic cancer patients may spontaneously develop a specific,
MHC-independent cytotoxic T-cell response against epitopes in
the protein core of tumour-associated MUC1 (Jerome et al, 1991);
however, MHC class I and class II restricted cellular immune
reactions against MUC1 protein were observed as well (Aposto-
lopoulos et al, 1997; Hiltbold et al, 1998; Reddish et al, 1998;
Brossart et al, 1999; Pietersz et al, 2000; Heukamp et al, 2001).
Although anti-MUC1 responses are frequently detected in patients
with advanced and progressing adenocarcinomas (Nakamura et al,
1998), activation of immunological effector cells is obviously not
sufficient to protect against tumour progression in vivo. Natural B-
cell responses to lactation- or tumour-associated glycoforms of the
mucin, as detected in women after pregnancy or in some cancer
patients, improve survival rates, but usually do not eliminate the
MUC1þ tumour cells in vivo. Accordingly, enhancement of
endogenous immune responses to MUC1 by active specific
immunisation based on designed MUC1 vaccines is predicted to
improve long-term survival of patients with MUC1þ adenocarci-
nomas. Recent evidence suggests that the induction of a strong
anti-MUC1 response in cancer patients may require the activation
of specific T helper cells via MHC class II presented peptide and
glycopeptide epitopes, a process that is controlled by site-specific
O-glycosylation (Vlad et al, 2002). CD4-mediated responses
generated against MUC1 apparently do not fit the type 1 or 2
model (VanLith et al, 2002), and the involvement of natural killer
cells (NK cells) in MUC1-based immunity has been demonstrated.
The search for immunological strategies that allow an MUC1-
specific and locally restricted activation of effector cells in the
vicinity of the tumour could lead to alternative therapeutical tools. Revised 15 July 2003; accepted 17 July 2003
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sWe here made use of an immunocytokine to modulate
specifically and locally the immune response. The concept of
immunocytokines is based on fusion proteins composed of
a cytokine for the activation of immune cells and of an
antibody-derived binding domain for specific targeting of the
cytokine (Lode et al, 1998). Strategies based on antifolate
receptor scFv or anticarcinoembryonic antigen scFv were
successfully evaluated in transgenic mouse models (Melani et al,
1998; Xu et al, 2000) proving the principal of the approach as
promising. A panel of antibodies were raised against the tumour-
associated form of the MUC1 antigen, particularly against the
protein core motif (Price et al, 1997). The anti-MUC1 monoclonal
antibody (mAb) C595 reacts with the peptide motif RPAP in the
repeat sequence of the protein core (Price et al, 1990). C595mAb
has been used in immunoassays for the measurement of soluble
MUC1 in breast cancer patients (Price et al, 1992; Dixon et al,
1993) and for in vivo immunoscintigraphy (Symonds et al, 1992;
Perkins et al, 1993). The C595mAb has been converted into a
single-chain fragment of variable regions (scFv) with retained
binding specificities (Denton et al, 1997). Utilising the C595 scFv,
we generated an anti-MUC1-scFv-Fc-IL2 fusion protein that after
binding to MUC1-positive tumour cells induces proliferation of
peripheral blood T cells and mediates activation of resting NK cells
to lysis of MUC1-positive tumour cells. Results presented here
suggest the C595scFv-Fc-IL2 fusion protein as suitable immuno-
cytokine for the specific immune modulation in the vicinity of
MUC1-positive tumours.
MATERIALS AND METHODS
Cell lines
The human mammary carcinoma cell line T-47D (HTB-133, ATCC,
Rockville, MD, USA) was cultured in RPMI 1640 medium
supplemented with 2mML -glutamine (Sigma, Deisenhofen, Ger-
many), 0.2Uml
 1 insulin (Novo Nordisk, Mainz, Germany) and
10% (vv
 1) fetal calf serum (FCS, Biochrome KG, Berlin,
Germany). The human mammary carcinoma cell line MCF7
(HTB-22, ATCC) and the human renal carcinoma line 293T
expressing the SV40 large T antigen (Pear et al, 1993) were
maintained in DME medium with 10% (v/v) FCS. The Hodgkin’s
lymphoma-derived cell line L540 (Diehl et al, 1983) was cultured in
RPMI 1640 medium, 2mML -glutamine, 10% (v/v) FCS.
MUC1 glycoforms
Native MUC1 glycoforms were isolated from human milk fat
globule membranes as described previously (Mu ¨ller et al, 1997). A
partially deglycosylated derivative of the lactation-associated
glycoform was generated by treatment with trifluoromethane
sulfonic acid for 30min at 01C (Mu ¨ller et al, 1997).
Chemical synthesis and purification of MUC1 peptides and
glycopeptides
Glycopeptides A13, A9 and H4 corresponding to MUC1 tandem
repeat peptides based on the AHG21 sequences AHGVTSAPDTR-
PAPGSTAPPA (A13, A9) and AHGVTSAPESR PAPGSTAPAA (H4)
and carrying GalNAc at Thr/Ser10 (A13, H4) or at multiple sites
(refer to Table 1) were chemically synthesised according to
previously published protocols (Paulsen et al, 1995) and isolated
successively on preparative and analytical reversed-phase columns
on an HPLC workstation (System Gold, Beckman, Mu ¨nchen,
Germany). The peptides TAP25 and AHG21-AES were chemically
synthesised by a local facility at the Center of Biochemistry
(Medical Faculty of the University of Cologne) and isolated on a
preparative C18 reversed-phase column AQ20S11153OR
(150 30mm, YMC Europe GmbH). TR3 (60-mer) with repetitive
PAP20 sequence was a kind gift of Dr Jo Hilgers (previously at
Academisch Ziekenhuis, Amsterdam, The Netherlands) and TR5
(100-mer) with repetitive GVT20 was kindly provided by Dr.
Olivera Finn (Department of Immunology, University of Pitts-
burgh, Pittsburgh, PA, USA).
Monoclonal antibodies
C595 is a monoclonal antibody (IgG3, kappa light chain)
with specificity for MUC1 urinary mucin (Price et al, 1990).
The recombinant antibody fragment C595scFv was derived
from the C595 antibody and is composed of the VH and VL
variable regions joined via a (Gly4Ser)3 linker peptide (Denton
et al, 1997).
Construction and expression of the MUC1-specific fusion
proteins C595scFv-Fc and C595scFv-Fc-IL2
The cDNA encoding the human IgG1 CH2/CH3 domain (Shu et al,
1993) as well as the IL2 cDNA, derived from Jurkat cells (TIB-152,
ATCC), were terminally equipped by polymerase chain reaction
PCR with BamHI and XhoI restriction sites, respectively, using the
following oligonucleotide primers:
hIgG-50[50-CTGAAGGATCCCGCCGAGCCCAAATCTCCTGACA-
AAACT-30],
hIgG-Stop-30[50-GGCCTCGAGCTAGATCTTACCCGGAGACAG-
GGA-30],
50-hIL2,[50-GATCAGGATCCGGTGATCAAAGCACCTACTTCAA-
GTTCTACA-30],
30-hIL2, [50-TCAACTCGAGTCGACTCAAGTCAGTGTTGAGAT-
GAT-30] (restriction sites are underlined). The PCR products were
ligated into the corresponding sites of the expression vector pRSV-
HRS3scFv-g that encodes a CD30-specific recombinant immunor-
eceptor (Hombach et al, 1998). Thereby, the FceRIg signalling
domain is replaced by the cDNA coding for the human IgG1
constant domain and the IL2 cDNA, respectively. The DNA
encoding the single-chain antibody fragment C595scFv was
flanked by PCR with nucleotide sequences containing XbaI and
BamHI restriction sites (underlined), respectively, utilising the
primer oligonucleotides VH50,5 0-[GCGGCCCAGTCTAGAATGG
CCCAG]-30 and C595VL30,5 0-[CGCACCTGGATCCGCCCGTTT-
CAGCTGCAG]-30. The amplified C595 scFv DNA was subsequently
inserted into the corresponding sites of pRSV-HRS3scFv-Fc
DNA herewith replacing the HRS3 scFv domain. To construct
the C595scFv-Fc-IL2 expression cassette, the C595scFv-Fc
DNA was amplified by PCR and flanked with SnaBI and
Table 1 (Glyco)peptides used in this study corresponding to sections of
the human MUC1 repeat domain
Designation Structure
TR3 (60-mer) (PAPGSTAPPAHGVTSAPDTR)3
TR5 (100-mer) (GVTSAPDTRPAPGSTAPPAH)5
TAP25 TAPPAHGVTSAPDTRPAPGSTAPPA
AHG21-AES AHGVTSAPESRPAPGSTAPAA
A13 AHGVTSAPDTRPAPGSTAPPA
H4 AHGVTSAPESRPAPGSTAPAA
A11 HGVTSAPDTRPAPGSTAPPA
A9 AHGVTSAPDTRPAPGSTAPPA
O-Glycosylation sites are indicated as GalNAc or Gal   GalNAc, respectively.
Sequence variations according to a polymorphism in the tandem repeat domain
(Engelmann et al, 2001) are indicated by bold letters. TR5, 100-mer peptide, was
kindly provided by Dr Olivera Finn, University of Pittsburgh, USA; TR3, 60-mer
peptide, was obtained Dr. Jo Hilgers, previously at Academisch Ziekenhuis,
Amsterdam, The Netherlands; TAP25 and AHG21-AES were synthesised in a local
facility, and the glycopeptides were prepared by Professor Hans Paulsen, University of
Hamburg, Germany.
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DNA pRSV-C595scFv-Fc as template and the oligonucleotide
primers Lkappa-50 [50-CTACGTACCATGGATTTTCAGGTGCA-
GATTTTC-30] and hIgG1-30(BglII) [50-CCCACCCAGATCTTTTT-
TACCCGGAGACAGGGAGAGGCTCTTCTG-30]. The PCR product
was ligated into the vector construct pRSV-HRS3scFv-
IL2 replacing the HRS3scFv binding domain. For expression
of the recombinant anti-MUC1 fusion proteins, 293T cells
were transfected by calcium phosphate techniques with 10–20mg
of the plasmid DNA pRSV-C595scFv-Fc and pRSV-C595scFv-
Fc-IL2, respectively. After 48–72h the cell culture supernatants
were harvested and analysed for the presence of the fusion
proteins.
ELISA to detect the anti-MUC1 fusion proteins
Serial dilutions of the cell culture supernatant of transfected 293T
cells were incubated in microtitre plates coated with an anti-
human IgG antibody (1mgml
 1, Southern Biotechnology, Birming-
ham, AL, USA). Bound fusion proteins were detected by a
biotinylated anti-human IgG antibody (0.125mgml
 1, Southern
Biotechnology) or, alternatively, by a biotin-labelled anti-human
IL2 antibody (0.5mgml
 1, BD Biosciences/PharMingen). The
assays were developed by means of a streptavidin-coupled
peroxidase and ABTS substrate (both Roche Diagnostics, Mahn-
heim, Germany).
Sodium dodecyl sulphate–polyacrylamide gel
electrophoresis and Western blot analysis
The cell culture supernatant of transfected 293T cells was
electrophoretically separated by sodium dodecylsulphate poly-
acrylamide gel electrophoresis (SDS–PAGE) and blotted onto
nitrocellulose membrane. The membrane was blocked with Roti
s-
Block (Roth GmbH, Karlsruhe, Germany) containing 5% milk
powder and subsequently incubated with a horseradish peroxidase
(HRP)-conjugated rabbit anti-human IgG antibody (1:20000,
Dako, Hamburg, Germany) or with a mouse anti-human IL2
antibody (1:250, Serotec, Du ¨sseldorf, Germany), followed by
incubation with a rabbit anti-mouse IgG-HRP conjugate (1:20000,
Dako), respectively. The blots were developed by means of the
ECLt detection reagent (Amersham Pharmacia Biotech, Freiburg,
Germany).
Antigen-binding assays
Binding of the C595scFv-Fc and C595scFv-Fc-IL2 fusion proteins
was monitored by ELISA using partially deglycosylated MUC1
from human milk fat membranes (Mu ¨ller et al, 1997) as well as a
set of synthetic peptides and glycopeptides (Table 1).
Microtitre plates (maxi-sorp, Nunc, Roskilde, Denmark) were
coated with the peptide antigens (10mgml
 1), partially deglycosy-
lated MUC1 from human milk (100mgml
 1), BSM (100mgml
 1)
and for control reason with an anti-human IgG antibody and an
anti-mouse IgG1 antibody, respectively (both 1mgml
 1, Southern
Biotechnology). After blocking the microtitre plates were incu-
bated with cell culture supernatants containing the fusion proteins
C595scFvFc and C595scFv-Fc-IL2, respectively, with the mono-
clonal antibody C595 (250ngml
 1), and for control with a murine
IgG1 monoclonal antibody (250ngml
 1, Sigma). Bound fusion
proteins and antibodies were detected with biotin-labelled anti-
isotypic goat anti-human IgG and goat anti-mouse IgG antibody
(both 125ngml
 1, Southern Biotechnology). The assays were
developed by means of a streptavidin-coupled peroxidase and
ABTS substrate (both Roche Diagnostics).
To compare the antigen-binding capacity of the fusion proteins
C595scFv-Fc and C595scFv-Fc-IL2, respectively, with that of the
parental mAb C595, microtitre plates (maxi-sorp, Nunc) were
coated with the peptide antigen TR5 (2.5mgml
 1), blocked and
subsequently incubated with serial dilutions of cell culture
supernatants containing the fusion proteins C595scFv-Fc and
C595scFv-Fc-IL2, respectively, and dilutions of the parental mAb
C595. The fusion proteins and the mAb bound to the microtitre
plates were detected by biotin-labelled secondary antibodies as
described above. Dilutions of supernatants and antibody resulting
in half-maximal absorbance at 405nm were applied to plates with
immobilised TR5 antigen (2.5mgml
 1). Binding was assayed in the
presence of increasing concentrations of soluble TR5 antigen (up
to 20mgml
 1). The percentage of binding inhibition was calculated
as follows:
inhibitionð%Þ¼
1  
absorbanceð405nmÞinthepresenceof competitor
absorbanceð405nmÞintheabsenceof competitor

 100
Immunofluorescence and flow cytometry
Immunofluorescence assays were performed by incubation of
T-47D cells (MUC1þ/CD25 ), 293T cells (MUC1 /CD25 )
and L540 cells (MUC1 /CD25þ) with cell culture supernatant
of transfected 293T cells containing the fusion protein C595scFv-
Fc and C595scFv-Fc-IL2, respectively, and as control with
supernatant of mock-transfected 293T cells. Alternatively,
fusion proteins were incubated with resting peripheral blood
lymphocytes (PBL) or lymphocytes activated with IL2 (400Uml
 1)
and anti-CD3 antibody OKT3 (100ngml
 1). Bound fusion proteins
were detected by an FITC-labelled F(ab0)2 anti-human IgG
antibody (2mgml
 1, Southern Biotechnology). The IL2 receptor
(a-chain) was detected by incubation of PBL with an FITC-
conjugated anti-CD25 antibody (clone B1.49.9, Coulter-Immuno-
tech Diagnostics, Hamburg, Germany). Immunofluorescence
assays were analysed utilising a FACScant cytofluorometer
equipped with the Cellquestt analysis software (Becton Dickinson,
Mountain View, CA, USA).
Proliferation assays
Peripheral blood lymphocytes from healthy donors were isolated
from peripheral blood by density centrifugation and cultured
for 24 to 48h in RPMI 1640 medium supplemented with
10% (v/v) FCS, IL2 (400Uml
 1), and anti-CD3mAb OKT3
(100ngml
 1). Activated lymphocytes were washed twice and
cultured for additional 48h in RPMI 1640 medium containing
10% (v/v) FCS, IL2 (400Uml
 1). Peripheral blood lymphocytes
were washed twice and cultured for 3h in the absence of IL2.
Subsequently 2.5 10
5 PBL per well were cultured in the presence
of serial dilutions of cell culture supernatant containing the fusion
proteins C595scFv-Fc-IL2 or C595scFv-Fc and for control IL2
(2000Uml
 1), respectively. After 72h, lymphocyte proliferation
was quantified by means of the ‘XTT cell proliferation kit’ (Roche
Diagnostics) according to the manufacturer’s recommendations.
Alternatively, activated PBL were cultured in the presence of
fusion protein bound to immobilised antigen. Microtitre plates
(maxi-sorp, Nunc) were coated with increasing amounts of MUC1
antigen, TR5 glycopeptide, and asialo-BSM, respectively (up to
100mgml
 1). After blocking, the coated wells were incubated with
cell culture supernatants containing the fusion proteins C595scFv-
Fc and C595scFv-Fc-IL2. The plates were washed three times with
PBS and lymphocytes (2.5 10
5 per well) were added. After culture
for 72h, proliferation was monitored utilising ‘XTT cell prolifera-
tion kit’ (Roche Diagnostics).
Alternatively, polystyrene-coated ferric oxide beads M-280
(tosylated, Dynal, Hamburg, Germany) were covalently coated
with TR5 peptide antigen and for control reason with human
Anti-MUC1-scFv-IL2 fusion protein
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The beads were incubated with cell culture supernatants of
transfected 293T cells containing the fusion proteins C595scFv-
Fc and C595scFv-Fc-IL2, respectively, and supernatant of un-
transfected 293T cells. Specific binding of the fusion proteins to
TR5-coated beads was monitored by flow cytometry utilising a
FITC-labelled F(ab’)2 anti-human IgG antibody (2mgml
 1, South-
ern Biotechnology). After three times of washing, serial dilutions of
coated beads were seeded onto 96-well microtiter plates (15710
5–
0.6710
5 beads/well) and activated lymphocytes (2 10
5cells–
well) were added. After 72h, proliferation was determined as
described.
Cytotoxicity assay
Tumour cell viability was monitored by an XTT-based colorimetric
assay according to Jost et al. (1992). Briefly, PBL from healthy
donors were isolated by density centrifugation and NK cells were
negatively enriched by magnetic activated cell sorting (MACS)
utilising the ‘NK Cell Isolation Kit’ (Miltenyi Biotec, Bergisch
Gladbach, Germany). MUC-1-positive MCF7 cells or T47D cells
were incubated with cell culture supernatants containing
C595scFv-Fc and C595scFv-Fc-IL2 fusion protein, respectively,
and for control with medium with and without IL2 (400Uml
 1).
After four times of washing, coated target cells were seeded onto
round-bottomed microtiter plates (5 10
4 cells per well) together
with resting NK cells (1 10
5 per well). In a second set of
experiments, untreated tumour cells (5 10
4 per well) were
cocultured with NK cells (1 10
5 per well) in the presence of the
soluble fusion protein C595scFv-Fc-IL2 and IL2 (400Uml
 1),
respectively. After 48h, the XTT reagent (1mgml
 1, ‘Cell
Proliferation Kit II’, Roche Diagnostics) was added to the cells
and incubated for 60–90min at 371C. Metabolisation of XTT to a
formazan was monitored colorimetrically at an adsorbance
wavelength of 450nm and a reference wavelength of 650nm.
Maximal reduction of XTT was determined as the mean of three
wells containing tumor cells only, and background was determined
as the mean of three wells containing RPMI 1640 medium, 10%
(vv
 1) FCS. The formation of formazan due to the effector cells
was determined from triplicate wells containing NK cells only. The
percentage of viable tumour cells was calculated as follows:
Viabilityð%Þ¼
absorbanceð450   650nmÞexperimentalwells   correspondingeffectorcells
absorbanceð450   650nmÞtumourcells   withouteffectorcells   medium
 100
RESULTS
Expression of the recombinant fusion proteins C595scFv-
Fc and C595scFv-Fc-IL2
We generated the expression constructs pRSV-C595scFv-Fc and
pRSV-C595scFv-Fc-IL2 that code for fusion proteins consisting of
the anti-MUC1 scFv C595 and the human IgG1 CH2CH3 domain
(Fc domain) with or without linked IL2, respectively (Figure 1).
After transient transfection, 293T cells secrete the fusion proteins
into the cell culture medium as monitored by ELISA (Figure 2).
Whereas both proteins are captured by the anti-human IgG
antibody directed against the Fc domain of the fusion proteins,
only the C595scFv-Fc-IL2 immunocytokine is detected by the anti-
human IL2 antibody. Western blot analysis revealed that the
C595scFv-Fc fusion protein migrates at about 120kDa and the
C595scFv-Fc-IL2 fusion protein at about 150kDa under nonredu-
cing conditions (Figure 3A) corresponding to the homodimeric
forms of the respective fusion proteins. Western blot analysis
C595scFv
XbaI BamHI XhoI
Fc Lκ
SnaBI
C595scFv
XbaI BamHI XhoI
Fc Lκ  
SnaBI
IL-2
XbaI
Figure 1 Expression cassettes coding for the recombinant anti-MUC1
fusion proteins C595scFv-Fc and C595scFv-Fc-IL2. The expression
cassettes were generated as described in Materials and Methods. Lk:
leader sequence of the Ig k chain; C595scFv: anti-MUC1 scFv; Fc: IgG1
CH2CH3. The expression cassettes are driven by the RSV LTR.
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Figure 2 Detection of the fusion proteins C595scFv-Fc and C595scFv-
Fc-IL2 in the supernatants of transfected 293T cells. Serial dilutions of
culture supernatants from 293T cells transfected with pRSV-C595scFv-Fc
(’), pRSV-C595scFv-Fc-IL2 (K) and, as control, from mock-transfected
cells (*), respectively, were incubated in microtitre plates coated with an
anti-human IgG antibody. Bound fusion proteins were detected by a biotin-
labelled anti-human IgG (A) or anti-human IL2 (B) antibody.
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IL2 fusion protein (Figure 3B).
Fusion proteins bind specifically to MUC1
The fusion proteins C595scFv-Fc and C595scFv-Fc-IL2 and the
mAb C595 were tested by ELISA for binding to partially
deglycosylated MUC1 antigen from human milk fat membranes
as well as to a set of MUC1 glycopeptides corresponding to parts of
the repeat domain and containing the RPAP motif (Table 1). As
shown in Figure 4, the binding patterns of the fusion proteins to
the panel of MUC1-derived antigens are similar to that of the
monoclonal antibody C595 indicating that the C595 scFv domain
in the fusion proteins conserved the antigen-binding profile of the
parental C595mAb. The profile is characterised by (i) binding to
DTRPAP-containing repeat peptides (Table 1), (ii) no cross-
reactivity to ESRPAP-containing repeat peptides (AHG21-AES,
H4), which represent a known sequence polymorphism in the
tandem repeat domain of the mucin (Hanisch and Mu ¨ller, 2000;
Engelmann et al, 2001), (iii) stronger binding to oligorepeats (TR3
and TR5) and native MUC1 (MUC1deglyco) than to monorepeats
(TAP25), and (iv) inhibition of antibody binding due to O-
glycosylation of the peptides (A13, A11, A9).
We furthermore compared the binding properties of the
recombinant proteins C595scFv-Fc and C595scFv-Fc-IL2, respec-
tively, to that of the mAb C595 by competition assays utilising
dilutions of the fusion proteins and of mAb C595, respectively, that
lead to half-maximal binding. Binding to immobilised TR5 peptide
was assayed in the presence of increasing amounts of soluble TR5
peptide. As summarised in Figure 5, binding of both fusion
~ 120 kDa
~ 150 kDa
A
12 3 12 3
~ 20 kDa
B
Figure 3 The fusion proteins C595scFv-Fc and C595scFv-Fc-IL2 are
expressed as homodimers. Cell culture supernatants from 293T cells
transfected with pRSV-C595scFv-Fc DNA (lane 1) or with pRSV-
C595scFv-Fc-IL2 DNA (lane 2) as well as recombinant human IL2 (1000
U, lane 3) were electrophoretically separated under nonreducing
conditions, blotted onto nitrocellulose membrane and probed with an
anti-human IgG antibody (A) and an anti-human IL2 antibody (B). The
calculated molecular weight of the monomeric form of the fusion protein
C595scFv-Fc is 60kDa, of the C595scFv-Fc-IL2 protein is 75kDa.
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Figure 4 Antigen binding profile of the recombinant fusion proteins
C595scFv-Fc and C595scFv-Fc-IL2. Microtitre plates were coated with a set
of MUC1-related (glyco-) peptides (10mgml
 1) corresponding to mono-
and oligorepeats and containing the RPAP motif (see Table 1), partially
deglycosylated MUC1 antigen (100mgml
 1), and, as control, BSM
(100mgml
 1), an anti-human IgG antibody (1mgml
 1) and an anti-mouse
IgG antibody (1mgml
 1), respectively. The coated wells were incubated
with cell culture supernatants containing the fusion proteins C595scFv-Fc
(A) and C595scFv-Fc-IL2 (B), respectively, and as control with the mAb
C595 (C) and a mouse IgG1 control antibody (D) (both 0.25mgml
 1).
Bound fusion proteins and antibodies were detected by a biotin-labelled
anti-human IgG mAb (A and B) or a biotin labelled anti-mouse IgG mAb
(C and D). The assay was performed in triplicate; data are presented as the
mean7s.e.m.
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sproteins C595scFv-Fc and C595scFv-Fc-IL2 is titrated out by
increasing concentrations of soluble TR5 peptide. The apparent
antigen-binding affinities of the recombinant fusion proteins,
however, are reduced by a factor of 2–3 compared to that of the
mAb C595 in this assay.
The fusion proteins were furthermore assayed by flow cytometry
for binding to MUC1-expressing tumour cells. As demonstrated in
Figure 6A, both fusion proteins C595scFv-Fc and C595scFv-Fc-IL2
bind to cells of the MUC1-positive line T-47D but not to cells of the
MUC1-negative 293T line. The fusion proteins bind to polystyrene
ferric oxide beads coated with TR5 peptide, but do not bind to
beads coated with human serum albumin as control. C595scFv-Fc-
IL2 protein, moreover, binds to the IL2 receptor (CD25)
constitutively expressed on the surface of MUC1-negative L540
cells. Binding of C595scFv-Fc-IL2 to the IL2 receptor is specific
because (i) the C595scFv-Fc fusion protein that lacks the IL2
domain does not bind to MUC1
  CD25
þ L540 cells (Figure 6A),
and (ii) C595scFv-Fc-IL2 binds to activated lymphocytes with
increased CD25 expression after stimulation with the anti-CD3
antibody OKT3 plus IL2, but does not bind to resting lymphocytes
that do not express the IL2 receptor (Figure 6B). As control, the
C595scFv-Fc protein without IL2 domain does not bind to resting
lymphocytes, but binds weakly via the C595 scFv domain to
activated T cells that express Muc1 (Agrawal et al, 1998). Taken
together, the fusion proteins C595scFv-Fc and C595scFv-Fc-IL2
specifically bind to MUC1-positive tumour cells via the anti-MUC1
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Figure 5 Binding-inhibition assay. Microtitre plates coated with the
peptide antigen TR5 (2.5mgml
 1) were incubated with dilutions of
C595scFv-Fc (K), C595scFv-Fc-IL2 (’), and C595mAb (m), respectively,
that result in half-maximal binding. The binding to immobilized TR5 antigen
was specifically competed by addition of increasing amounts of soluble TR5
antigen. Bound fusion proteins were detected by the biotin-labelled anti-
human IgG antibody; bound C595mAb was detected by the biotinylated
anti-mouse IgG antibody. The percentage of inhibition was determined as
described in ‘Material and Methods’.
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Figure 6 Fusion proteins C595scFv-Fc and C595scFv-Fc-IL2 bind specifically to MUC1 positive tumour cells and TR5 peptide-coated beads. Cell culture
supernatants from transfected 293T cells containing the C595scFv-Fc and C595scFv-Fc-IL2 fusion protein (thick lines), respectively, and, as control,
supernatant from 293T cells transfected with an irrelevant DNA (thin lines), were incubated (A) with T-47D cells (MUC1þ/CD25 ), 293T cells
(MUC1 /CD25 ), L540 cells (MUC1 /CD25þ), TR5 peptide-coated beads or, as control, with human serum albumin-coated beads, and (B) with
quiescent lymphocytes from the peripheral blood (PBL) or with PBL activated by preincubation with the anti-CD3mAb OKT3 plus IL2. Bound fusion
proteins were detected by an FITC-labelled anti-human IgG antibody. Expression of the IL2 receptor CD25 was monitored by incubation with a FITC-
conjugated anti-CD25mAb (anti-CD25).
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sscFv domain, the C595scFv-Fc-IL2 protein binds in addition via
IL2 to CD25
þ, activated lymphocytes in vitro.
C595scFv-Fc-IL2 fusion protein induces proliferation of
activated lymphocytes
We assessed the IL2 bioactivity of the C595scFv-Fc-IL2 fusion
protein by monitoring the induction of proliferation of activated
lymphocytes. As shown in Figure 7, the C595scFv-Fc-IL2 protein
stimulates proliferation of activated lymphocytes in a dose-
dependent manner, whereas the C595scFv-Fc protein that lacks
the IL2 domain does not. Incubation of activated lymphocytes with
IL2 served as control. Resting T cells, in contrast, are not activated
to proliferate in the presence of the C595scFv-Fc-IL2 fusion
protein (data not shown).
To assay whether the C595scFv-Fc-IL2 fusion protein retains its
IL2 bioactivity after binding to MUC1 antigen, we incubated
C595scFv-Fc-IL2 protein, and C595scFv-Fc protein as control, on
plastic surfaces coated with MUC1 or TR5 peptide, respectively.
Bound to MUC1 and TR5 antigen, respectively, the C595scFv-Fc-
IL2 protein stimulates proliferation of activated lymphocytes in a
dose-dependent manner, whereas no lymphocyte proliferation was
detected in the presence of the bound C595scFv-Fc fusion protein
(Figure 8A, B). As control, plates coated with asialo-BSM and
incubated with the C595scFv-Fc-IL2 fusion protein did not induce
proliferation of activated lymphocytes (Figure 8C).
In a second assay, tosylated ferric oxide beads were coated with
TR5 peptide, or with human serum albumin as a control, and
subsequently incubated with the fusion proteins C595scFv-Fc-IL2
and C595scFv-Fc, respectively. Binding of the fusion proteins on
TR5-coated beads was confirmed by FACS analysis (Figure 6A). As
summarised in Figure 8D, C595scFv-Fc-IL2 fusion protein bound
to TR5-coated beads stimulates proliferation of activated lympho-
cytes in a dose-dependent manner, whereas C595scFv-Fc control
protein does not. As control, beads coated with human serum
albumin and incubated with the fusion proteins did not induce
proliferation of activated lymphocytes (Figure 8E).
C595scFv-Fc-IL2 fusion protein induces resting NK cells to
lysis of MUC1-positive tumour cells
We assayed the bioactivitiy of the C595scFv-Fc-IL2 fusion protein
bound to MUC1-positive target cells by monitoring the activation
of resting NK cells to lyse target cells. MUC1-positive MCF7
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Figure 7 Activated lymphocytes proliferate in the presence of soluble
C595scFv-Fc-IL2 fusion protein. Lymphocytes from the peripheral blood
(2.5 10
5cells per well) were activated by incubation with the anti-
CD3mAb OKT3 plus IL2 and cultured in the presence of cell culture
supernatants containing the fusion proteins C595scFv-Fc-IL2 (K),
C595scFv-Fc (’), and as control IL2 (m) (2000Uml
 1), respectively.
After 72h, lymphocyte proliferation was quantified by means of the ‘XTT
cell proliferation kit’ (Roche Diagnostics). The assays were performed in
triplicate; data are presented as mean7s.e.m.
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Figure 8 C595scFv-Fc-IL2 fusion protein bound to MUC1 antigen
stimulates proliferation of activated lymphocytes. Micotitre immunoplates
were coated with increasing amounts of deglycosylated MUC1 (A),
TR5 peptide (B), and asialo-BSM (C), respectively, and subsequently
incubated with cell culture supernatants containing the fusion proteins
C595scFv-Fc (’) and C595scFv-Fc-IL2 (K), respectively. After extensive
washing, activated lymphocytes (2.5 10
5 per well) were incubated in
coated plates for 72h. In a second set of experiments, beads coated with
TR5 peptide antigen (D) and, as control, coated with human serum
albumin (E) were incubated with culture supernatant containing the fusion
protein C595scFv-Fc or C595scFv-Fc-IL2, respectively, washed extensively
and incubated in serial dilutions (15 10
5–0.6 10
5beads per well) with
activated lymphocytes (2.5 10
5 per well). After 72h, lymphocyte
proliferation was quantified by means of the ‘XTT cell proliferation kit’.
The assays were performed in triplicate; data are presented as the
mean7s.e.m.
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stumour cells were incubated with C595scFv-Fc-IL2 fusion protein
and IL2, respectively, and cocultured with resting NK cells.
Tumour cell viability was monitored by an XTT-based colorimetric
assay. As shown in Figure 9A, C595scFv-Fc-IL2 protein induced
resting NK cells to lysis of MCF7 cells as does IL2 indicating that
the fusion protein is capable to activate resting NK cells.
In a second assay, MCF7 cells were preincubated with C595scFv-
Fc-IL2, C595scFv-Fc, and IL2 as control, respectively, washed
intensively, and subsequently coincubated with resting NK cells.
As shown in Figure 9B, MCF7 cells coated with C595scFv-Fc-IL2
protein were significantly lysed by NK cells compared to
preincubation with C595scFv-Fc protein without the IL2 domain.
Soluble IL2 not bound to MCF7 cells and washed out did not
induce NK-cell-mediated cytolysis indicating that soluble IL2 is
substantially eliminated by repeated washings prior to coincuba-
tion with NK cells. Essentially, the same results were obtained
when using Muc1
þ T-47D cells in the assay (Figure 9B). This set of
experiments demonstrates that the C595scFv-Fc-IL2 fusion protein
bound to MUC1-positive tumour cells activates resting NK cells to
tumour cell lysis.
DISCUSSION
The purpose of this study was to engineer a novel immunother-
apeutic reagent that is directed to MUC1-positive tumour cells and
activates effector responses of NK cells. Activation of resting NK
cells in particular is expected to be of significance considering
recent evidences that NK cells may contribute to MUC1 immunity
and that the MUC1 directed immune response does not fit the type
1 or type 2 model (VanLith et al, 2002). In the light of these
findings the insufficient outcomes of multiple efforts to stimulate
an MUC1-specific CD4
þ or CD8
þ T-cell response may find an
explanation.
The anti-MUC1 scFv-Fc-IL2 fusion protein harbours the C595
scFv domain for targeting IL2 to MUC1-positive tumours. C595
scFv represents, to our best knowledge, the only example of a
successful attempt to generate high-affinity anti-DTR MUC1-
specific scFv from phage libraries or from established hybridoma
clones. This antibody defines a peptide motif more upstream of the
DTR sequence (RPAP). We here demonstrate that the conservative
replacement of Asp-Thr within the sequence PDTRPAP by Glu-Ser
has a severe negative impact on the binding of both, the parental
antibody C595 and the scFv-Fc-IL2 fusion protein, which indicates
a contribution of these two residues to the epitope structure of the
C595 antibody. The replacement of DT by ES represents a
sequence polymorphism found with a high incidence in all repeat
domains of human MUC1, which were analysed on the level of
genomic DNA (Engelmann et al, 2001). The C595 scFv binds to a
panel of mammary and bladder carcinoma biopsies but not to
benign tissues like breast ducts (Denton et al, 1997) making the
scFv suitable for specific tumour cell binding.
The C595scFv-Fc-IL2 fusion protein is expressed as homodimer
(cf. Figure 3) that is likely to be formed by disulphide bonds
between the IgG1 Fc domains incorporated into the fusion protein
between the scFv and IL2 moiety. Utilising a panel of MUC1
mucins and peptides, we here demonstrate that the C595scFv-Fc-
IL2 fusion protein exhibits the same binding specificity as the
C595mAb (Figure 4), however, with slightly reduced avidity
compared to that of the mAb C595 (Figure 5). The C595scFv-Fc-
IL2 fusion protein binds specifically to the IL2 receptor on
activated lymphocytes, but not to resting lymphocytes that do not
express the IL2 receptor (Figure 6B). C595scFv-Fc weakly binds to
activated lymphocytes, most likely via the C595scFv domain to
Muc1 expressed on activated T cells (Agrawal et al, 1998).
Although C595scFv-Fc-IL2 binds much stronger to activated
lymphocytes via CD25, binding to activated T cells and dendritic
cells via Muc1 cannot be excluded. Noteworthy, binding to resting
T cells was not observed (cf. Figure 6B).
C595scFv-Fc-IL2 fusion protein stimulates proliferation of
activated lymphocytes from the peripheral blood in a dose-
dependent manner, whereas the C595scFv-Fc protein that lacks
the IL2 domain does not. The IL2 activity of the fusion protein to
induce proliferation of activated T cells is still conserved after
binding to MUC1 mucin (cf. Figure 8). Resting T cells that do not
express the IL2 receptor (CD25) are not activated by the fusion
protein. Resting NK cells, in contrast, are activated by the C595scFv-
Fc-IL2 fusion protein to tumour cell lysis (cf. Figure 9). These
results are of major significance because (i) the fusion protein is
designed to act locally in the near vicinity of the tumour after
binding to MUC1-positive tumour cells and (ii) the fusion protein
activates resting NK cells and preactivated T cells thereby recruiting
both compartments of the cellular immune response. Noteworthy,
resting T cells are not activated thereby avoiding an immune
response of T cells that are not activated in the tumour environment
and may be of nontumour-related specificities (not shown).
Strategies during the last years to improve the cellular immune
responses against MUC1 protein include: (i) conjugation of MUC1
peptides with KLH or mannan (Karanikas et al, 1997; Gilewski et al,
2000), (ii) coexpression of MUC1 with CD80 (B7.1) in tumour cells
to provide costimulatory signals to the immune system (Smith
et al, 1999), (iii) fusing MUC1-positive tumour cells with antigen-
presenting cells or pulsing dendritic cells with MUC1-derived
peptides (Brossart et al, 2000; Gong et al, 2000), (iv) application of
MUC1 together with Th1 cytokines (Acres et al, 2000; Carr-Brendel
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Figure 9 The fusion protein C595scFv-Fc-IL2 activates resting NK cells
to tumour cell lysis (A). MCF7 cells (MUC1
þ)( 5 10
4cells per well) were
cocultured with resting NK cells (1x10
5 cells per well) in the presence of
C595scFv-Fc-IL2 fusion protein or IL2 (400Uml
 1). As control, MCF7 cells
were cocultured with NK cells in cell culture medium without additives. (B)
MCF7 and T-47D tumour cells (MUC1
þ) were preincubated with cell
culture supernatants containing C595scFv-Fc, C595scFv-Fc-IL2, or IL2
(400Uml
 1), respectively. After four rounds of washings, cells were
seeded into round-bottom microtiter plates (5 10
4cells per well) and
cocultured with resting NK cells (1 10
5 cells per well). The viability of
MCF7 and T-47D cells was determined by an XTT-based viability assay as
described in Material and Methods. The assays were performed in triplicate;
data are presented as the mean7s.e.m. Statistical significance was
determined utilising Student’s t-test.
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set al, 2000; Lees et al, 2000; Mukherjee et al, 2003), and (v) use of a
BCG-MUC1-IL2 fusion protein (He et al, 2002). The latter fusion
protein consists of the BCG antigen signal sequence, the MUC1
VNTR core peptide, and IL2. Immunisation of SCID/hu-PBL mice
with the fusion protein resulted in increased MUC1-specific
cellular immunity suggesting that combined application of
MUC1 peptide and IL2 may mediate an effective immunity against
MUC1-positive cancer. As far as clinical studies were performed on
the basis of the above-cited approaches, the outcomes were
insufficient in terms of the strength and longevity of the cellular
immune responses. On the other hand, passive transfer of MUC1-
specific antibodies did not affect the growth of MUC1 expressing,
experimentally transplanted melanomas in a mouse model
(Tempero et al, 1999). In this model, CD4
þ T cells were critical
for rejection of MUC1-positive tumours (Tempero et al, 1998;
VanLith et al, 2002), whereas other studies suggest that CD8
þ T
cells are required for MUC1-specific immunity against MUC1-
positive pancreatic carcinoma (Morikane et al, 2001).
Although in vitro detection of cytolytic activity does not always
correlate with in vivo tumour rejection, the potential of the
C595scFv-Fc-IL2 fusion protein to activate immunocompetent
resting NK and preactivated T cells after binding to MUC1-positive
tumour cells is clearly demonstrated. Suppressive effects of the
tumour environment, including locally accumulated suppressive
cytokines, and other stromal elements may additionally modulate the
efficacy of the fusion protein in vivo. The fusion protein, however,
provides a specific tool to increase stimulatory signals to both
activated T and resting NK cells in the vicinity of MUC1-positive
tumour cells in order to improve the antitumour immune response.
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